Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Neuroprotection Program
Cardioprotection Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Neuroprotection Program
Cardioprotection Program
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Key Dates
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
15-Jun-2021
Improved Drug Candidate Selected for WRAIR Studies
11-May-2021
Notice of Extraordinary General Meeting/Proxy Form
6-May-2021
Nyrada Receives A$1.0M R&D Tax Incentive Rebate
5-May-2021
NYR Announces New Potent Cholesterol-Lowering Candidates
26-Apr-2021
Change of Registered Office and Principal Place of Business
20-Apr-2021
Nyrada Quarterly Activities Report & Appendix 4C
30-Mar-2021
Change in substantial holding
30-Mar-2021
Ceasing to be a substantial holder
30-Mar-2021
Change in substantial holding
30-Mar-2021
Cleansing Statement
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Next